Regeneron calls it quits on 4 studies of COVID med REGEN - Printable Version
+- SG Talk (https://sgtalk.net)
+-- Forum: SG Talk (https://sgtalk.net/Forum-SG-Talk)
+--- Forum: Market Talk (https://sgtalk.net/Forum-Market-Talk)
+--- Thread: Regeneron calls it quits on 4 studies of COVID med REGEN (/Thread-Regeneron-calls-it-quits-on-4-studies-of-COVID-med-REGEN)
+- SG Talk (https://sgtalk.net)
+-- Forum: SG Talk (https://sgtalk.net/Forum-SG-Talk)
+--- Forum: Market Talk (https://sgtalk.net/Forum-Market-Talk)
+--- Thread: Regeneron calls it quits on 4 studies of COVID med REGEN (/Thread-Regeneron-calls-it-quits-on-4-studies-of-COVID-med-REGEN)
Regeneron calls it quits on 4 studies of COVID med REGEN - theold - 09-08-2022
The move comes about half a year after the FDA pulled the cocktail from the market after data suggested its efficacy had waned in the face of the surging omicron variant.
It’s a fate shared by a number of early-pandemic therapeutics, which have largely fallen by the wayside in the U.S. as the virus swiftly evolves.
Now, Regeneron has terminated four clinical trials of REGEN-COV, comprising the monoclonal antibodies casirivimab and imdevimab.
On the FDA’s online roster of pandemic emergency use authorizations, the regulator states that both Regeneron’s REGEN-COV and Lilly’s bamlanivimab and etesevimab are “not currently authorized in any U.S. region,” and therefore, “may not be administered for the treatment or post-exposure prevention of COVID-19.”
https://www.fiercepharma.com/pharma/regeneron-puts-kibosh-4-antibody-studies-pfizers-antiviral-paxlovid-dominates-treatment